Drug Profile
Research programme: tuberculosis vaccines - Aeras/China Center for Disease Control and Prevention
Latest Information Update: 28 Jul 2018
Price :
$50
*
At a glance
- Originator Aeras; China Center for Disease Control and Prevention
- Class Tuberculosis vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Tuberculosis
Most Recent Events
- 28 Jul 2018 No recent reports of development identified for research development in Tuberculosis in China
- 29 Aug 2013 Aeras receives 5-year grant from Department for International Development in the United Kingdom for vaccine development in tuberculosis
- 02 Aug 2013 Early research in Tuberculosis in China (unspecified route)